Abstract
Background: This systematic review and meta-analysis of randomized controlled trials (RCTs), were performed to determine the effects of curcumin intake on glycemic control and lipid profiles among patients with metabolic syndrome (MetS) and related disorders.
Methods: We searched the following databases up until January 2018: MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. The relevant data were extracted and evaluated for quality of the studies in accordance with the Cochrane risk of bias tool. Data were pooled using the inverse variance method and expressed as standardized mean difference (MDs) with 95% confidence intervals (95% CI).
Results: Twenty-six trials with 1890 participants were included in the current meta-analysis. The findings demonstrated the significant association between curcumin intake and reduced fasting glucose levels (SMD -0.78; 95% CI, -1.20, -0.37; P<0.001), homeostasis model of assessment-estimated insulin resistance (SMD -0.91; 95% CI, -1.52, -0.31; P=0.003) and HbA1c (SMD -0.92; 95% CI, -1.37, -0.47; P<0.001). In addition, curcumin supplementation was significantly associated with triglyceride (SMD -1.21; 95 % CI, -1.78, -0.65; P<0.001) and total cholesterol reduction (SMD -0.73; 95 % CI, -1.32, -0.13; P= 0.01). However, curcumin intake significantly increased insulin levels (SMD 0.92; 95% CI, 0.06, 1.78; P=0.036). We found no significant effect of curcumin supplementation on LDL- (SMD -0.52; 95% CI, -1.14, 0.11; P=0.10) and HDL-cholesterol levels (SMD 0.28; 95% CI, -0.22, 0.77; P=0.27).
Conclusion: Overall, curcumin consumption was associated with a significant reduction in fasting glucose, HOMA-IR, HbA1c, triglycerides and total cholesterol levels among patients with MetS and related disorders, but did not affect LDL- and HDL-cholesterol levels.
Keywords: Curcumin, glycemic control, lipid profiles, meta-analysis, Randomized Controlled Trials (RCTs), Metabolic Syndrome (MetS).
Current Pharmaceutical Design
Title:The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials
Volume: 24 Issue: 27
Author(s): Reza Tabrizi, Sina Vakili, Kamran B. Lankarani, Maryam Akbari, Naghmeh Mirhosseini, Majid Ghayour-Mobarhan, Gordon Ferns, Fatemeh Karamali, Maryam Karamali, Mohsen Taghizadeh, Ebrahim Kouchaki and Zatollah Asemi*
Affiliation:
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan,Iran
Keywords: Curcumin, glycemic control, lipid profiles, meta-analysis, Randomized Controlled Trials (RCTs), Metabolic Syndrome (MetS).
Abstract: Background: This systematic review and meta-analysis of randomized controlled trials (RCTs), were performed to determine the effects of curcumin intake on glycemic control and lipid profiles among patients with metabolic syndrome (MetS) and related disorders.
Methods: We searched the following databases up until January 2018: MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. The relevant data were extracted and evaluated for quality of the studies in accordance with the Cochrane risk of bias tool. Data were pooled using the inverse variance method and expressed as standardized mean difference (MDs) with 95% confidence intervals (95% CI).
Results: Twenty-six trials with 1890 participants were included in the current meta-analysis. The findings demonstrated the significant association between curcumin intake and reduced fasting glucose levels (SMD -0.78; 95% CI, -1.20, -0.37; P<0.001), homeostasis model of assessment-estimated insulin resistance (SMD -0.91; 95% CI, -1.52, -0.31; P=0.003) and HbA1c (SMD -0.92; 95% CI, -1.37, -0.47; P<0.001). In addition, curcumin supplementation was significantly associated with triglyceride (SMD -1.21; 95 % CI, -1.78, -0.65; P<0.001) and total cholesterol reduction (SMD -0.73; 95 % CI, -1.32, -0.13; P= 0.01). However, curcumin intake significantly increased insulin levels (SMD 0.92; 95% CI, 0.06, 1.78; P=0.036). We found no significant effect of curcumin supplementation on LDL- (SMD -0.52; 95% CI, -1.14, 0.11; P=0.10) and HDL-cholesterol levels (SMD 0.28; 95% CI, -0.22, 0.77; P=0.27).
Conclusion: Overall, curcumin consumption was associated with a significant reduction in fasting glucose, HOMA-IR, HbA1c, triglycerides and total cholesterol levels among patients with MetS and related disorders, but did not affect LDL- and HDL-cholesterol levels.
Export Options
About this article
Cite this article as:
Tabrizi Reza, Vakili Sina , Lankarani B. Kamran , Akbari Maryam , Mirhosseini Naghmeh , Ghayour-Mobarhan Majid , Ferns Gordon , Karamali Fatemeh , Karamali Maryam , Taghizadeh Mohsen , Kouchaki Ebrahim and Asemi Zatollah *, The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials, Current Pharmaceutical Design 2018; 24 (27) . https://dx.doi.org/10.2174/1381612824666180828162053
DOI https://dx.doi.org/10.2174/1381612824666180828162053 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potent Antihyperglycemic Effect of an Endemic Plant from Morocco (Matthiola Maroccana Coss.) on Normal and Streptozotocin-Induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Brittle Type 1 Diabetes Mellitus
Current Medicinal Chemistry Artificial Virus as Trump-card to Resolve Exigencies in Targeted Gene Delivery
Mini-Reviews in Medicinal Chemistry Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology A New Approach to the Inflammatory/Autoimmune Diseases
Recent Patents on Anti-Infective Drug Discovery Antiatherosclerotic and Cardioprotective Effects of Time-Released Garlic Powder Pills
Current Pharmaceutical Design Anti-Cancer Pyrimidines in Diverse Scaffolds: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Metformin: A Rising Star to Fight the Epithelial Mesenchymal Transition in Oncology
Anti-Cancer Agents in Medicinal Chemistry Repaglinide and Metformin-Loaded Amberlite Resin-Based Floating Microspheres for the Effective Management of Type 2 Diabetes
Current Drug Delivery Lifestyle Modification with Physical Activity Promotion on Leptin Resistance and Quality of Life in Metabolic Syndrome - A Systematic Review with Meta-Analysis
Current Diabetes Reviews Poly(Ethylene Glycol)-block-Poly(ε-Caprolactone) Nanomicelles for the Solubilization and Enhancement of Antifungal Activity of Sertaconazole
Current Drug Delivery The Impact of Uremic Toxins on Alzheimer's Disease
Current Alzheimer Research The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry Chromatin Remodeling, DNA Damage Repair and Aging
Current Genomics Expression and Antibody Preparation of POU Transcription Factor qBrn-1
Protein & Peptide Letters Immobilization of Proteins in Alginate: Functional Properties and Applications
Current Organic Chemistry Inhibitors of 17β-Hydroxysteroid Dehydrogenases
Current Medicinal Chemistry Laboratory-Based Studies of Eating Among Children and Adolescents
Current Nutrition & Food Science Editorial: Still Water Runs Deep
Current Molecular Medicine